StocksFundsScreenerSectorsWatchlists
MACK

MACK - Merrimack Pharmaceuticals Inc Stock Price, Fair Value and News

14.75USD+0.03 (+0.20%)Market Closed

Market Summary

MACK
USD14.75+0.03
Market Closed
0.20%

MACK Stock Price

View Fullscreen

MACK RSI Chart

MACK Valuation

Market Cap

214.3M

Price/Earnings (Trailing)

-149.58

Price/Sales (Trailing)

43.48

EV/EBITDA

373

Price/Free Cashflow

-142.9

MACK Price/Sales (Trailing)

MACK Profitability

Operating Margin

-40.77%

EBT Margin

-31.38%

Return on Equity

-7.64%

Return on Assets

-7.47%

Free Cashflow Yield

-0.7%

MACK Fundamentals

MACK Revenue

Revenue (TTM)

4.9M

MACK Earnings

Earnings (TTM)

-1.4M

Earnings Growth (Yr)

36.88%

Earnings Growth (Qtr)

28.64%

Breaking Down MACK Revenue

Last 7 days

0.3%

Last 30 days

0.6%

Last 90 days

12.5%

Trailing 12 Months

29.4%

How does MACK drawdown profile look like?

MACK Financial Health

Current Ratio

43.5

Debt/Equity

2.66

Debt/Cashflow

-0.03

MACK Investor Care

Dividend Yield

13.61%

Dividend/Share (TTM)

2

Shares Dilution (1Y)

1.94%

Diluted EPS (TTM)

-0.08

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
201902.8M3.8M4.9M
2017096.7M49.2M1.7M
201695.7M92.8M104.5M144.3M
2015104.6M113.3M101.7M89.3M
201446.2M55.5M76.7M102.8M
201352.2M58.6M54.2M47.8M
201239.1M44.6M47.3M48.9M
201123.8M27.3M30.7M34.2M
201000020.3M

Tracking the Latest Insider Buys and Sells of Merrimack Pharmaceuticals Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Dec 28, 2023
andersen eric
bought
11,441
13.3503
857
-
Dec 26, 2023
andersen eric
bought
640,313
13.15
48,693
-
Dec 07, 2023
andersen eric
bought
1,298,470
12.8498
101,050
-
Nov 17, 2023
andersen eric
bought
3,750
12.5
300
-
Nov 14, 2023
andersen eric
bought
627,125
12.5
50,170
-
Nov 13, 2023
andersen eric
bought
192,875
12.3876
15,570
-
Nov 10, 2023
andersen eric
bought
469,008
12.3222
38,062
-
Nov 09, 2023
andersen eric
bought
121,618
12.1923
9,975
-
Nov 08, 2023
andersen eric
bought
167,701
12.132
13,823
-
Aug 11, 2023
crocker gary l
bought
24,865
12.4326
2,000
see remarks

1–10 of 50

Which funds bought or sold MACK recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Mar 22, 2024
PNC FINANCIAL SERVICES GROUP, INC.
new
-
107
107
-%
Mar 11, 2024
VANGUARD GROUP INC
added
1.43
763,832
8,166,070
-%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
added
101
513,013
943,984
-%
Feb 28, 2024
AMERICAN INTERNATIONAL GROUP, INC.
reduced
-0.4
5,362
69,786
-%
Feb 16, 2024
Madison Avenue Partners, LP
unchanged
-
597,332
7,416,870
1.05%
Feb 15, 2024
Legal & General Group Plc
unchanged
-
1,389
17,245
-%
Feb 15, 2024
BARCLAYS PLC
added
679
170,000
193,000
-%
Feb 14, 2024
BANK OF AMERICA CORP /DE/
added
106
93,301
167,947
-%
Feb 14, 2024
Metropolitan Life Insurance Co/NY
unchanged
-
627
7,791
-%
Feb 14, 2024
KENNEDY CAPITAL MANAGEMENT LLC
reduced
-50.7
-535,851
619,569
0.01%

1–10 of 42

Are Funds Buying or Selling MACK?

Are funds buying MACK calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own MACK
No. of Funds

Unveiling Merrimack Pharmaceuticals Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Mar 07, 2024
blackrock inc.
4.99%
715,279
SC 13G/A
Feb 14, 2024
22nw fund, lp
-
0
SC 13G/A
Jan 31, 2024
blackrock inc.
5.2%
743,623
SC 13G
Jan 25, 2024
newtyn management, llc
13.1%
1,873,694
SC 13D/A
Dec 13, 2023
western standard llc
15.5%
2,220,058
SC 13D/A
Aug 14, 2023
western standard llc
13.9%
1,991,108
SC 13D/A
Feb 14, 2023
point72 asset management, l.p.
0%
0
SC 13G/A
Feb 13, 2023
22nw fund, lp
7.6%
1,015,048
SC 13G/A
Feb 14, 2022
nantahala capital management, llc
4.3%
569,971
SC 13G/A
Feb 14, 2022
22nw, lp
9.3%
1,241,896
SC 13G/A

Recent SEC filings of Merrimack Pharmaceuticals Inc

View All Filings
Date Filed Form Type Document
Mar 27, 2024
8-K
Current Report
Mar 27, 2024
DEFA14A
DEFA14A
Mar 22, 2024
DEFA14A
DEFA14A
Mar 21, 2024
10-K/A
Annual Report
Mar 21, 2024
DEF 14A
DEF 14A
Mar 07, 2024
SC 13G/A
Major Ownership Report
Mar 07, 2024
10-K
Annual Report
Mar 07, 2024
425
Prospectus Filed
Mar 07, 2024
8-K
Current Report
Mar 05, 2024
PRE 14A
PRE 14A

Peers (Alternatives to Merrimack Pharmaceuticals Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
42.3B
6.8B
19.31% -24.90%
-8.96
6.17
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.4B
1.8B
-0.33% -18.28%
-44.17
10.64
76.23% 61.08%
16.7B
2.4B
-4.10% -7.32%
99.73
6.91
15.42% 18.43%
12.8B
3.7B
-1.69% -18.94%
21.46
3.47
8.87% 75.42%
MID-CAP
7.1B
396.6M
-19.47% -8.81%
-13.34
17.78
425.83% 18.94%
5.4B
-
-20.51% 118.30%
-8.31
60.35
54.84% -34.79%
3.8B
270.6M
-13.09% 29.37%
-15.68
13.86
440.80% -27.84%
3.6B
240.7M
-7.70% 7.49%
-11.98
14.77
-1.03% -92.09%
3.0B
726.4M
-28.51% -9.28%
-48.93
4.13
40.45% 71.62%
SMALL-CAP
1.9B
398.2M
12.36% 9.77%
26.85
4.82
85.90% -14.05%
678.8M
983.7M
12.98% -18.87%
-1.25
0.69
-50.36% 17.16%
373.2M
881.7K
51.26% 463.55%
-8.37
466.16
-77.61% -5.33%
304.5M
4.9M
46.53% -11.16%
-2.25
62.57
-54.97% 51.72%
11.8M
2.1M
-13.49% -43.81%
-0.43
2.14
-13.45% 66.37%

Merrimack Pharmaceuticals Inc News

Latest updates
Seeking Alpha • 8 hours ago
Yahoo Movies Canada • 24 Mar 2024 • 03:11 pm
InvestorPlace • 08 Mar 2024 • 08:00 am
Simply Wall St • 14 Feb 2024 • 08:00 am

Merrimack Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2019Q42019Q32019Q22017Q42017Q32017Q22016Q42016Q32016Q22016Q12015Q42015Q32015Q22015Q12014Q42014Q32014Q22014Q12013Q42013Q32013Q2
Revenue---1.00-20.0041.0061.0028.0034.0021.0021.0016.0037.0015.0034.0028.0028.0013.008.007.0018.00
Cost Of Revenue-------3.001.002.001.000.00----------
Costs and Expenses----17.0017.0035.0042.0036.0036.0034.00-9.6355.0055.0045.0039.0052.0042.0037.0036.0043.0048.00
Operating Expenses161.3%2.001.009.00------------------
  S&GA Expenses-49.1%2.004.006.00------------------
  R&D Expenses---5.0012.0014.0020.0026.0028.0028.0028.0038.0030.0026.0026.0031.0044.0034.0030.00---
Interest Expenses-0.00-1.004.002.0027.002.002.0016.003.005.004.004.005.005.005.005.005.004.00--
Income Taxes-----10.03-2.13-30.24--9.77-------------
Earnings Before Taxes-Infinity%-2.15---21.86-7.46-59.88-43.54-36.61-51.63------------
Net Income562.6%3.00-0.70-9.43-12.95-----------------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-0.6%19.0019.0019.0020.0020.0014.0014.0015.0015.0015.0016.0016.0017.0019.0020.0021.0020.0025.0045.0074.0089.00
  Current Assets-0.6%19.0019.0019.0020.0020.0014.0014.0015.0015.0015.0016.0016.0017.0019.0019.0020.0019.0022.0043.0064.0076.00
    Cash Equivalents-1.5%6.006.0010.0019.0019.0013.0013.0014.0014.0015.0015.0014.0014.0016.0016.0018.0017.0021.0037.0037.0021.00
  Net PPE--------------------1.002.00
Liabilities-10.5%0.000.000.000.001.000.000.001.001.001.001.001.001.002.002.003.003.005.005.0025.0030.00
  Current Liabilities-10.5%0.000.000.000.001.000.000.001.001.001.001.001.001.002.002.003.003.005.005.0012.0015.00
Shareholder's Equity-0.3%19.0019.0019.0019.0019.0013.0014.0014.0014.0015.0015.0016.0016.0017.0017.0018.0017.0020.0040.0049.0059.00
  Retained Earnings0.0%-548-548-548-547-547-547-546-546-546-545-545-544-543-542-541-540-540-543-543-533-523
  Additional Paid-In Capital0.0%566566566566566559559559559559559559558558558557557563582581581
Shares Outstanding0.2%14.0014.0014.0014.0014.0013.0013.0013.0013.0013.0013.0013.00---------
Float-------57.00---68.00---44.00---79.00--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations-20.3%-273-227-644-356-185-264-939-354-355-4451,019-437-1,776135-1,979-1,005-2,640-3,203-11,873-13,652-18,892
Cashflow From Investing101.8%68.00-3,845-8,811139---445-94.00-50.00---3112,4505,0006,50028,21030,115-10,823
Cashflow From Financing-133-209179-------239-----6,638-19,940---
  Dividend Payments-----------------6,700----

MACK Income Statement

2023-12-31
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Operating expenses:  
General and administrative expenses$ 2,176$ 2,174
Gain on sales of assets(139)(445)
Total operating expenses2,0371,729
Loss from operations(2,037)(1,729)
Other income and expenses:  
Interest income868188
Total other income and expenses868188
Loss before income tax expense(1,169)(1,541)
Income tax expense(12)(3)
Net loss and comprehensive loss$ (1,181)$ (1,544)
Net loss per common share - basic$ (0.08)$ (0.11)
Net loss per common share - diluted$ (0.08)$ (0.11)
Weighted-average common shares used to compute basic net loss per common share14,29913,524
Weighted-average common shares used to compute diluted net loss per common share14,29913,524

MACK Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 5,989,000$ 19,439,000
Short-term investments12,886,0000
Prepaid expenses and other current assets309,000389,000
Total current assets19,184,00019,828,000
Other assets4,0008,000
Total assets19,188,00019,836,000
Current liabilities:  
Accounts payable, accrued expenses and other441,000589,000
Total current liabilities441,000589,000
Total liabilities441,000589,000
Commitments and contingencies
Stockholders’ equity:  
Preferred stock, $0.01 par value: 10,000 shares authorized at December 31, 2023 and 2022 no shares issued or outstanding at December 31, 2023 or 2022
Common stock, $0.01 par value: 30,000 shares authorized at December 31, 2023 and 2022; 14,351 and 14,215 shares issued and outstanding at December 31,2023 and 20221,343,0001,342,000
Additional paid-in capital566,221,000565,541,000
Accumulated deficit(548,817,000)(547,636,000)
Total stockholders’ equity18,747,00019,247,000
Total liabilities and stockholders’ equity$ 19,188,000$ 19,836,000
MACK
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
0
 CEO
 WEBSITEwww.merrimack.com

Merrimack Pharmaceuticals Inc Frequently Asked Questions


What is the ticker symbol for Merrimack Pharmaceuticals Inc? What does MACK stand for in stocks?

MACK is the stock ticker symbol of Merrimack Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Merrimack Pharmaceuticals Inc (MACK)?

As of Wed Mar 27 2024, market cap of Merrimack Pharmaceuticals Inc is 214.34 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MACK stock?

You can check MACK's fair value in chart for subscribers.

What is the fair value of MACK stock?

You can check MACK's fair value in chart for subscribers. The fair value of Merrimack Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Merrimack Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MACK so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Merrimack Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether MACK is over valued or under valued. Whether Merrimack Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Merrimack Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MACK.

What is Merrimack Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Mar 27 2024, MACK's PE ratio (Price to Earnings) is -149.58 and Price to Sales (PS) ratio is 43.48. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MACK PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Merrimack Pharmaceuticals Inc's stock?

In the past 10 years, Merrimack Pharmaceuticals Inc has provided -0.052 (multiply by 100 for percentage) rate of return.